A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia

What is the goal of the study?

Safety, tolerability, and pharmacokinetics of crinecerfont in participants with classic congenital adrenal hyperplasia who are less than 4 years old

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

• PI (Study Doctor): Patricia Fechner
• Study Team Member: Stephanie Purdy, [email protected]